EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 892 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with... August 17, 2026 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer August 21, 2021 Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... January 10, 2024 Load more HOT NEWS Are differences in treatment driving variation in ovarian cancer survival internationally? Colposcopia: Cómo prepararse y qué saber Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests No Improvement in OS or PFS from Sacituzumab Govitecan Compared with...
